维普中文期刊产品整合服务
564篇 您的检索式:作者名="Preiss"
    题名 作者 年代 出处 被引量
1吃熟肉可以显著改变血肌酐浓度与eGFR显示文摘编辑:Traynor等认为,摄入肉食对血肌酐的浓度以及eGFR的影响较小(见本期第28页)。但是MDRD试验中产生公式的数据主要来源于禁食的病人(AS Levey,个人交流)。但在临床实践中,测定血肌酐与eGFR的标本在采集时通常不考虑病人近期的饮食情况。David J Preiss Ian M Godber Ian R Gunu 隋准 2007英国医学杂志中文版2007,10,1:2
2A smooth variational principle with application to subdifferentiability 显示文摘BORWEIN J M PREISS D 1987Tran Amer Math Soc1987,303,:2
3Parameters of a severe disease course in ulcerative colitis显示文摘AIM:To detect high risk patients with a progressive disease course of ulcerative colitis(UC) requiring immunosuppressive therapy(IT).METHODS:A retrospective,multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed.Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course.A comparison between the two groups was made with regard to demographics,clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy.Using this data,a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy.RESULTS:In 104(39.7%) out of 262 patients,UC therapy required an immunosuppressive treatment.Patients in this group were significantly younger at time of diagnosis(HR = 0.981 ± 0.014 per year,P = 0.009),and required significantly more often a hospitalisation(HR = 2.5 ± 1.0,P < 0.001) and a systemic corticosteroid therapy at disease onset(HR = 2.4 ± 0.8,P < 0.001),respectively.Response to steroid treatment was significantly different between the two groups of patients(HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids,P = 0.016 to P < 0.001).Furthermore,in the IT group an extended disease(HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis,P = 0.007 to P = 0.001),anemia(HR = 2.2 ± 0.8,P < 0.001),thrombocytosis(HR = 1.9 ± 1.8,P = 0.009),elevated C-reactive protein(CRP)(HR = 2.1 ± 0.9,P < 0.001),and extraintestinal manifestations in the course of disease(HR = 2.6 ± 1.1,P = 0.004) were observed.Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT.This probability ranges from less than 2% up to 100% after 5 years.Using this,the necessity of an immunosuppressive therapy can be predicted in 60% of patients.Our model can determine the need for an immunosuppressive drug therapy or if a 'watch and wait' approach is reasonable already early in the treatment course of UC.CONCLUSION:Using six simple clinical parameters,we can estimate the patients individual risk of developing a progressive disease course.Andreas Stallmach Luisa Nickel Thomas Lehmann Bernd Bokemeyer Martin Bürger Dietrich Hüppe Wolfgang Kruis Susanna Nikolaus Jan C Preiss Andreas Sturm Niels Teich Carsten Schmidt 2014World Journal of Gastroenterology2014,20,35:2
4Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials显示文摘Naveed Sattar David Preiss Heather M Murray Paul Welsh Brendan M Buckley Anton JM de Craen Sreenivasa Rao Kondapally Seshasai John J McMurray Dilys J Freeman J Wouter Jukema Peter W Macfarlane Chris J Packard David J Stott Rudi G Westendorp James Shepherd 2010The Lancet2010,,9716:2
5Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials显示文摘Naveed Sattar David Preiss Heather M Murray Paul Welsh Brendan M Buckley Anton JM de Craen Sreenivasa Rao Kondapally Seshasai John J McMurray Dilys J Freeman J Wouter Jukema Peter W Macfarlane Chris J Packard David J Stott Rudi G Westendorp James Shepherd 2010The Lancet2010,,9716:2
6Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasrna gondii dopamine, a missing link between schizophrenia and toxoplasmosis? 显示文摘Flegr J Preiss M Klose J 2003BiolPsychol2003,63,3:1
7Treatment of murine Th1and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonueleotides显示文摘Fichtner FS Fuss LJ Preiss JC 2005J Clin Invest2005,115,11:1
8Comparison of protein of ADP-glucose pyrophorylase from diverse显示文摘SMITH WHITE B J PREISS J 1992J Mol Evol1992,34,:1
9Treatment of murine Th1-and Th2-mediated inflammatory bowel disease with NF-κB decoy oligodeoxyribonucleotides 显示文摘Fichtner-Fiegl S Fuss IJ Preiss JC 2005J Clin Invest2005,115,11:1
10Treatment of murine Thl- and Th2-mediated inflammatory bowel disease with NF-kappa B de- coy oligonueleotides 显示文摘Fiehtner-Feigl S Fuss IJ Preiss JC 2005J Clin Invest2005,115,11:1
11Non-alcoholic fatty liver disease:an overview of prevalence,diagnosis,pathogenesis and treatment considerations显示文摘Preiss D Sattar N 2008Clin Sci(Lond)2008,115,5:1
12Enzymatic synthesis of nicotinamide mono- nueleotide显示文摘Preiss J Handler P 1957J Biol Chem1957,225,2:1
13Non-alcoholic fatty liver disease: an overview of prevalence,diagnosis,pathogenesis and treatment considera- tions显示文摘Preiss D Sattar N 2008Clinical Science2008,115,5:1
14Studies on the carbothermal preparation of titanium carbide from diffrerent gel precursors显示文摘Henry Preiss 1999J Eur Ceram Soc1999,19,:1
15Cyclophosphamide and related anti- cancer drugs显示文摘BAUMANN F PREISS R 2001J Chromatogr B Biomed Sci Appl2001,764,12:1
16Geosynchronous space based radar concept development for theater surveillance显示文摘Fiedler S Preiss B 1996IEEE Aerospace Applications Conference1996,,2:1
17Compensation of visually simulated wind drift in the swarming flight of the desert locust (Schistocerca gregaria)显示文摘PREISS R GEWECKE M 1991Journal of Experimental Biology1991,157,:1
18Risk of incident diabeteswith intensive-dose compared with moderate-dose statin therapy:a meta-analysis显示文摘Preiss D Seshasai SR Welsh P 2011JAMA2011,305,24:1
19Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials显示文摘Sattar N Preiss D Murray HM 0,,9716:1
20Carbothermal synthesis of vanadium and chromium carbides from solution derived precursors 显示文摘Preiss H Schultzeb D Szulzewsky K 1999J Eur Ceram Soc1999,19,2:1
返回顶部 每页显示:
共29页 首页 上一页 第1页 下一页 末页 /29 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费